The bacterial pathogen Legionella pneumophila modulates host immunity using effectors translocated by its Dot/Icm transporter to facilitate its intracellular replication. A number of these effectors employ diverse mechanisms to interfere with protein ubiquitination, a post-translational modification essential for immunity. Here, we have found that L. pneumophila induces monoubiquitination of the E2 enzyme UBE2N by its Dot/Icm substrate MavC(Lpg2147). We demonstrate that MavC is a transglutaminase that catalyses covalent linkage of ubiquitin to Lys 92 and Lys 94 of UBE2N via Gln 40 . Similar to canonical transglutaminases, MavC possess deamidase activity that targets ubiquitin at Gln 40 . We identified Cys 74 as the catalytic residue for both ubiquitination and deamidation activities. Furthermore, ubiquitination of UBE2N by MavC abolishes its activity in the formation of K 63 -type polyubiquitin chains, which dampens NF-κ B signalling in the initial phase of bacterial infection. Our results reveal an unprecedented mechanism of modulating host immunity by modifying a key ubiquitination enzyme by ubiquitin transglutamination.
L egionella pneumophila extensively modulates host cellular processes with the hundreds of effectors injected by its Dot/Icm system, which results in the biogenesis of the Legionella-containing vacuole (LCV), a phagosome that supports bacterial replication 1 . Infection by L. pneumophila activates the major immune regulator NF-κ B by at least two mechanisms. The first is a transient Dot/ Icm-independent activation, most probably by immune agonists such as flagellin and lipopolysaccharide; this activation is more apparent when macrophages are challenged with bacteria at a high multiplicity of infection (MOI) 2, 3 . The second mechanism is mediated by the Dot/Icm transporter that persists throughout much of the intracellular life cycle of the bacterium 2,3 . NF-κ B activated by the latter mechanism induces the expression of a large repertoire of genes, including those involved in cell survival, vesicle trafficking and immunity 2, 4 . The Dot/Icm effector LegK1 activates NF-κ B by directly phosphorylating Iκ Bα and other members of this inhibitor family, including p100 (ref. 5 ); LnaB also activates this transcriptional factor, but its mechanism of action is unknown 6 . Cell survival genes induced by NF-κ B activation are required for productive intracellular bacterial replication 2 . The activation of immunity by ligands such as flagellin presumably is detrimental to the pathogen, but how L. pneumophila counteracts such defence remains unknown.
Among other important functions, ubiquitination is essential in the regulation of immunity against infection 7 . Classical ubiquitination is catalysed by the action of the E1, E2 and E3 enzymes, which function coordinately to covalently attach ubiquitin to protein substrates 8 . Interference of the host ubiquitin network is critical for the success of many microorganisms that have parasitic or symbiotic relationships with eukaryotic hosts, and such interference is often achieved by virulence factors that function as deubiquitinases, E3 ubiquitin ligases 9 or as ubiquitin modification enzymes 10 . More than ten Dot/Icm effectors of L. pneumophila function to hijack host ubiquitin signalling 11 . Among these, members of the SidE effector family catalyse ubiquitination by a two-step process that completely differs from the canonical three-enzyme cascade. In the reaction catalysed by SidEs, ubiquitin is first ADP-ribosylated at Arg 42 to produce the reaction intermediate ADPR-Ub 12 , which is utilized by a phosphodiesterase (PDE) activity also embedded in SidEs that transfers the phosphoribosylated ubiquitin to serine residues in their substrates 13, 14 .
In our efforts to identify eukaryotic proteins capable of catalysing ubiquitination with mechanisms similar to those used by SidEs, we found that the E2 enzyme UBE2N can be modified by a ubiquitin mutant unable to be used by the canonical ubiquitination machinery. Further studies revealed that UBE2N was monoubiquitinated during L. pneumophila infection by the effector MavC (Lpg2147). We also demonstrate that MavC functions as a transglutaminase that catalyses crosslinking between ubiquitin and UBE2N, leading to the inhibition of its activity in NF-κ B activation.
Results
Modification of UBE2N by a ubiquitin mutant that cannot be used by the canonical ubiquitination machinery. To identify potential eukaryotic enzymes capable of catalysing ubiquitination by a mechanism similar to that of SidEs, we expressed 3xHA-Ub and 3xHA-Ub-AA (the last two glycine residues were replaced with alanine residues) in HEK293T cells. Although their number was drastically reduced compared with those modified by 3xHA-Ub, proteins potentially modified by 3xHA-Ub-AA were detected ( Supplementary Fig. 1a ). We thus performed immunoprecipitation from cells expressing 3xHA-Ub-AA with HA antibody, and proteins in gels of relevant molecular weight (M w ) were identified by mass spectrometry analysis. Among the proteins identified, the E2 enzyme UBE2N important for the formation of K 63 -type polyubiquitin chains 15 was seen in multiple experiments (Supplementary Table 1 ). Subsequent experiments found UBE2N to be the only protein that can be detectably modified by 3xHA-Ub-AA in HEK293T cells ( Supplementary Fig. 1b ). UBE2N is modified by the Dot/Icm effector MavC(Lpg2147) during L. pneumophila infection. To identify the enzymes responsible for UBE2N ubiquitination with 3xHA-Ub-AA, we hypothesized that such enzymes may be induced under certain stress conditions. Clearly, the identification of such conditions would facilitate subsequent purification and characterization of the enzymes because of the potentially higher protein levels. Thus, we treated Raw264.7 cells with a variety of stresses and examined UBE2N ubiquitination. None of the tested physiochemical treatments led to a shift in M w in UBE2N (Fig. 1a ). In these experiments, we also included samples from cells infected with two L. pneumophila strains. Intriguingly, we observed a M w shift akin to monoubiquitination only in cells infected with the virulent strain (Fig. 1a ). The requirement of the Dot/Icm transporter suggests that such modification is caused by one or more of its substrates. We chose first to pursue this potential effector-induced UBE2N modification because it is technically more straightforward than identification of the mammalian proteins potentially involved in its modification.
To identify the Dot/Icm substrate(s) responsible for UBE2N modification, we took advantage of the several cluster deletion mutants of L. pneumophila 16 . With the exception of strain ∆ 5, infection by all of other mutants caused an MW shift in UBE2N ( Fig. 1b ). We thus identified the protein responsible for this modification by individually expressing effectors absent in strain ∆ 5 in HEK293T cells. These experiments revealed that Lpg2147 (MavC) 17 was able to cause UBE2N modification ( Fig. 1c) . We thus constructed and tested strain Lp02∆ mavC and found that infection with wildtype but not the mutant caused UBE2N modification ( Fig. 1d ). Furthermore, introduction of a plasmid expressing mavC restored the ability of the mutant to modify UBE2N (Fig. 1d ). The level of UBE2N modification corresponds well to the expression level of MavC in bacterial strains. The relatively lower modification rates in transfected cells may be due to low transfection efficiency ( Fig. 1e ). Thus, mavC is the only gene responsible for UBE2N modification during L. pneumophila infection.
In macrophages, the ∆ mavC strain grew at rates indistinguishable from that of the wild-type strain ( Supplementary Fig. 2a ), indicating that, similar to most Dot/Icm substrates, mavC is not required for proficient intracellular bacterial replication in commonly used tissue culture hosts. In broth-grown bacteria, MavC was barely detectable in the lag and early exponential growth phases (optical density at 600 nm (OD 600 ) of 0.05-2.2) but became highly expressed in exponential phase and continued to the post-exponential phase (OD 600 = 2.6-3.6) ( Supplementary Fig. 2b ), suggesting that MavC functions in the initial phase of infection.
MavC induces UBE2N ubiquitination by a mechanism that does not require the host ubiquitination machinery. Modification of UBE2N induced by MavC led to an ~10 kDa increase in its M w , a size close to monoubiquitination ( Fig. 1 catalyses ubiquitination, we incubated MavC, HA-Ub and 4xFlag-UBE2N with total lysates of HEK293T cells. A modified protein with a molecular weight similar to that of UBE2N-Ub was detected by HA-specific antibody ( Fig. 2a ), indicating that MavC utilizes HA-Ub to modify UBE2N. Importantly, we observed indistinguishable UBE2N modification by HA-Ub in reactions containing boiled total cell lysates ( Fig. 2a , rightmost lane), suggesting that the activity of MavC may not need the host ubiquitination machinery. We next used biochemical assays to test the hypothesis that MavC is a ubiquitin ligase whose activity does not require components of the canonical ubiquitination reaction. To function as an E2 enzyme, UBE2N requires another protein such as UBE2V2 to form a heterodimer 18 . In reactions that contained all the necessary components, modified UBE2N was produced ( Fig. 2b , top, rightmost lane). Unexpectedly, ubiquitination of UBE2N also occurred in reactions that did not receive the E1 enzyme ( Fig. 2b , top, leftmost lane). Such modification also occurred in reactions that did not receive Mg 2+ or ATP (Fig. 2b , top, sixth and seventh lanes). Importantly, self-ubiquitination occurred in MavC, again even in reactions that did not receive E1, Mg 2+ or ATP (Fig. 2b , bottom, first, sixth and seventh lanes). These results further suggest that MavC is capable of catalysing ubiquitination by a mechanism that does not require components of the canonical ubiquitination machinery.
Infection with a L. pneumophila strain overexpressing MavC led to modification of about 80% of endogenous UBE2N (Fig. 1d ). In contrast, the rates of modification were considerably lower in reactions containing purified proteins, suggesting that MavC requires one or more cellular factors for optimal activity. The addition of ATP or NAD did not increase the modification efficiency ( Fig. 2c ). Instead, lysates of prokaryotic or eukaryotic cells allowed the modification to proceed more completely and boiling treatment did not abolish such activity ( Fig. 2c ). Thus, one or more heat-stable factors were required for full activity of MavC. We tested the effects of several metal ions and found that a few divalent ions including Cu 2+ , Mn 2+ , Co 2+ and Ni 2+ were able to enhance the activity of MavC ( Fig. 2d,e ). Together, these results indicate that MavC catalyses ubiquitination by a mechanism that does not require components of the canonical ubiquitination machinery or even an exogenous energy source. Furthermore, its activity can be potentiated by several divalent metal ions such as Mn 2+ and Ni 2+ .
MavC is a transglutaminase that catalyses crosslinking between ubiquitin and UBE2N. We analysed the biochemical mechanism underlying MavC-mediated ubiquitination by determining the sites of ubiquitination on UBE2N and the chemical bond that links these two molecules. The protein band corresponding to modified UBE2N was analysed by liquid chromatographytandem mass spectrometry (LC-MS/MS) ( Fig. 3a) , which led to the identification of two UBE2N peptides, -I 86 CLDILKDK 94 -and -D 93 KWSPALQIR 102 -, which were crosslinked to the same ubiquitin fragment, -E 34 GIPPDQQR 40 - (Fig. 3b ,c). The fragmentation pattern and the fact that trypsin digestion did not occur at Lys 92 and Lys 94 in these UBE2N peptides suggest that the linkage is through a lysine residue. The tandem mass spectra also showed that ubiquitin is linked to the substrate through its Gln 40 residue (Fig. 3b,c ). By the mass difference, Gln 40 of ubiquitin was linked to a lysine residue in UBE2N by eliminating an ammonia molecule, leading to the formation of an N ε -(γ -glutamyl)lysine isopeptide bond between Gln 40 on ubiquitin and Lys 92 or Lys 94 of UBE2N (Fig. 3b,c) . The chemical linkage that bridges ubiquitin and UBE2N resembles those formed by transglutaminases (TGases), which often catalyse transamidation between the γ -carboxamide group of a glutamine residue in one protein and the ε -amino group of a lysine residue in another protein 19 . The reaction catalysed by TGases requires a Cys-His-Asp catalytic triad in which the Cys residue is involved in the formation of a γ -glutamylthioester with the Gln-containing protein (ubiquitin here) ( Fig. 3d) 20 . To identify the Cys residue critical for the activity of MavC, we constructed substitution mutants lacking each of its six Cys residues and examined their activity in UBE2N ubiquitination. Only mutation in Cys 74 abolished the ability of MavC to induce UBE2N ubiquitination ( Fig. 3e ).
We confirmed the modification sites on UBE2N by testing mutants with substitutions in Lys 92 or Lys 94 . Whereas incubation of the K94A mutant with MavC and ubiquitin still led to robust modification, ubiquitination of the K92A mutant was largely abolished and no modification was detected in reaction containing UBE2N K92AK94A (Fig. 3f ). Mutation in C87, the residue important for UBE2N's role as an E2 enzyme 18 , did not affect MavC-mediated modification (Fig. 3f ). Thus, the transglutamination reaction catalysed by MavC links ubiquitin to Lys 92 or Lys 94 of UBE2N, of which Lys 92 is the major modification site.
We next examined the role of the catalytic cysteine in ubiquitination of UBE2N during L. pneumophila infection. Unlike the ∆ mavC mutant expressing MavC, expression of MavC C74A did not cause UBE2N modification, despite the mutant protein being properly expressed and translocated into host cells (Fig. 3g ). MavC then reacts with the amine donor from the ε -lysine in UBE2N to form an intermolecular isopeptide bond. e, Cys 74 is essential for the activity of MavC. Flag-tagged MavC or its mutants harbouring mutations in each of its six Cys residues were expressed in HEK293T cells. The modification of UBE2N was probed by immunoblotting with a UBE2N-specific antibody (top). The Cys74Ala mutation did not affect the expression and stability of MavC (bottom). f, Lys 92 is the major ubiquitination site in UBE2N. 4xFlag-UBE2N or its mutants were incubated with ubiquitin and MavC. The formation of Ub-UBE2N was detected by immunoblotting. Note that the UBE2N K92A mutant has largely lost the ability to be modified (third lane). g, Cys 74 of MavC is essential for UBE2N ubiquitination induced by L. pneumophila. HEK293 cells were infected with the indicated bacterial strains for 2 h and the modification of UBE2N was probed by immunoblotting. The expression (bottom) and translocation (middle) of MavC and its mutant were probed with MavC-specific antibodies. Experiments in a-c and e-g were repeated at least three times and similar results were obtained.
We also determined the ability of MavC to modify several structurally similar E2s (harbouring Cys 87 and Lys 92 , not necessarily at the 87th and 92th residue, respectively) ( Supplementary Fig. 3a ). None of these E2s, including UBE2E2, 2K and 2S, was detectably ubiquitinated by MavC in either biochemical reactions or in cells infected by L. pneumophila ( Supplementary Fig. 3b ,c). These results suggest that MavC specifically modifies UBE2N.
The involvement of Gln 40 in the formation of the covalent bond suggests that residues important for ubiquitination catalysed by the canonical mechanism are not required for MavC-induced UBE2N modification. Indeed, each of the lysine mutants (lacking one, more or all of the lysine residues) was active at levels comparable to wildtype ubiquitin, as was the mutant in which the last two glycine residues were replaced with alanine ( Supplementary Fig. 4 ).
MavC possesses deamidation activity against ubiquitin.
In the absence of a suitable amine donor, the γ -glutamylthioester formed between the TGase and the substrate (ubiquitin here) can be hydrolysed to a free glutamate residue, which corresponds to a net deamidation of the substrate 21 . We thus examined the product of the reaction containing MavC and ubiquitin. Incubation of ubiquitin with MavC altered the mobility of ubiquitin in a way similar to the product produced by bacterial ubiquitin deamidases 10 ( Supplementary Fig. 5a ). Expectedly, deamidation by MavC required Cys 74, a residue critical for the transglutamination activity ( Supplementary Fig. 5c ). Unlike Cif and CHBP (ref. 10 ), MavC does not detectably attack NEDD8, indicative of substrate specificity ( Supplementary Fig. 5a ). In mass spectrometry analysis, deamidation can be easily misassigned by automated peptide identification algorithms with the 13 C isotope of peptides because they differ from each other by only 0.019 Da. Yet, the high-resolution mass spectrometry analysis revealed a peak at m/z 520.7531, which is closer to the deamidated (δ = 1.7 ppm) than the 13 C isotope (δ = 38.4 ppm) mass of the ubiquitin peptide -E 34 GIPPDQQR 40 -( Supplementary  Fig. 5b ). Furthermore, only trace amounts of the unmodified peptide were detected at m/z 520.2608 in a series of reactions containing MavC and different amounts of ubiquitin. After 1 h incubation, modified ubiquitin became detectable in reactions in which the ratio between ubiquitin and MavC is 64 and the modification was almost complete when this ratio was 16 ( Supplementary Fig. 5c ). Thus, similar to other transglutaminases, MavC catalyses a deamidation reaction on ubiquitin in the absence of UBE2N.
The observation that Gln 40 of ubiquitin provided the side chain required for ubiquitination predicts that a mutant with a substitution mutation in this residue can no longer be used in the reaction. Indeed, UBE2N cannot be modified by ubiquitin Q40E (Supplementary Fig. 5d ). Thus, similar to canonical transglutaminases from eukaryotic cells, MavC deamidates the protein that provides the glutamine residue 22 .
Transglutamination is the dominant activity of MavC in reactions containing UNE2N and ubiquitin. We examined the catalytic activity of MavC through a series of reactions in which UBE2N and MavC were added at different molar ratios. Under our experimental conditions, the modification of UBE2N by MavC was still readily detectable within 1 h when the molar ratio between MavC and UBE2N was as low as 1:1,900, and approximately 50% of UBE2N was modified when the ratio was 1:120 ( Fig. 4a ).
To examine which activity is dominant, we established reactions in which the molar ratios of MavC to UBE2N and ubiquitin were 60 and 1,024, respectively. A portion of the reaction was withdrawn at different time points after adding MavC to analyse the extent of UBE2N modification and ubiquitin deamidation. Ubiquitinated UBE2N became detectable right after (0 min) the addition of MavC and peaked at 20 min when ~50% of the protein was modified ( Fig. 4b, left ). In contrast, deamidated ubiquitin was barely detectable even after the reaction had proceeded for 2 h (Fig. 4b, right ).
Deamidated ubiquitin can be detected in cells transfected to express MavC but not MavC C74A ( Supplementary Fig. 6a,b) ; it is also detectable in cells infected with an L. pneumophila strain overexpressing MavC but not with wild-type strain ( Supplementary  Fig. 6c,d ), suggesting that the deamidase activity associated with MavC becomes detectable only when the protein level was artificially increased. Thus, MavC is highly active against UBE2N and that transglutamination is its dominant activity.
Ubiquitination of UBE2N by MavC abolished its E2 activity. UBE2N forms heterodimers with proteins such as UBE2V1
and UBE2V2 to function as an E2 that catalyses the elongation of K 63 -type ubiquitin chains 18 , which regulate multiple cellular processes 23 . Inclusion of MavC, but not MavC C74A , in reactions containing HA-Ub, the UBE2N-UBE2V2 complex and the E3 enzyme TRAF6 drastically reduced the production of polyubiquitin chains (Fig. 5a ). The loss of E2 activity was equally apparent when purified UNE2N-Ub was used in reactions ( Fig. 5b) . UBE2N and MavC at the indicated molar ratios were established and the reactions were allowed to proceed for 1 h before probing for the modified proteins (top). MavC was also detected (bottom). b, Transglutamination occurs faster than deamidation. A series of reactions with a 1:60 molar ratio for MavC and UBE2N were allowed to proceed for the indicated time durations. Modification was detected by Coomassie staining. Note that Ub-UBE2N was detectable immediately after adding MavC (0 min, left) and deamidated ubiquitin was barely detectable after 120 min incubation (right). Experiments in all panels were repeated at least three times and similar results were obtained.
MavC dampens the NF
a rapid decrease in Iκ Bα , which, after reaching the lowest point at 30 min post-infection, began to recover. Importantly, this decrease occurred significantly faster in infections using the ∆ mavC mutant (Fig. 5c ). The recovery of Iκ Bα in cells infected with the mutant was also slower (Fig. 5c ). Furthermore, the decrease of cellular Iκ Bα caused by mavC deletion can be restored by expressing MavC but not the C74A mutant (Fig. 5d ). Notably, Iκ Bα in cells infected with the complementation strain overexpressing MavC accumulated at significantly higher levels than those infected with wild-type bacteria (Fig. 5d ).
In line with the above results, ectopic expression of mavC attenuated NF-κ B activation in response to multiple distinct stimuli. The activation of NF-κ B by both tumour necrosis factor-α (TNF-α ) and phorbol myristate acetate (PMA) was inhibited in cells expressing MavC but not MavC C74A ( Supplementary Fig. 7a,b) . Similarly, NF-κ B activation induced by ectopic expression of Nod1, Myd88, TRAF6 and Bcl10 (refs [24] [25] [26] ) was inhibited by MavC ( Supplementary Fig. 7c-f ).
The observation that ubiquitination of UBE2N inhibited NFκ B activation predicts that cells expressing UBE2N K92A will be resistant to MavC. Indeed, NF-κ B activation was not affected by MavC in cells expressing UBE2N K92A (Fig. 6a ). Consistent with this observation, MavC cannot inhibit the activation induced by overexpressing p65 (Fig. 6b ). We also compared MavC to YopJ and Cif, which inhibit NF-κ B activation by IKKβ acetylation and ubiquitin deamidation, respectively 10, 27 . These proteins exerted similar inhibitory effects (Fig. 6c ). Yet, whereas IKKβ or TAK1/TAB1 suppressed the inhibitory effects caused by MavC, neither of them suppressed the inhibition imposed by Cif (Fig. 6d,e ). Together, these results indicate that ubiquitination of UBE2N by MavC is responsible for the inhibition of NF-κ B activation.
The inhibitory effects of MavC predict that its expression will lead to the sequestration of p65 in the cytosol on stimulation. Indeed, in cells expressing MavC, TNF-α treatment did not cause p65 nucleus translocation ( Supplementary Fig. 8 ). In contrast, in cells expressing the MavC C74A mutant, TNF-α stimulation led to p65 nucleus localization in almost every cell ( Supplementary Fig. 8 ). Similarly, p65 nucleus translocation occurred in ~75% of the cells infected with strain ∆ mavC, which was significantly higher than those infected with wild-type bacteria ( Supplementary Fig. 9 ). Notably, infections with the ∆ mavC strain overexpressing MavC reduced nucleus translocation of p65 to ~20% ( Supplementary Fig. 9 ), which further supports its inhibitory role in NF-κ B activation. Taken together, these results indicate that MavC regulates host immunity by interfering with NF-κ B activation during L. pneumophila infection.
Discussion
Immune cells respond to damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) via various receptors, and this dictates the outcome of the interaction between a pathogen and its hosts. Pathogens have evolved various strategies to counter the host immune response to ensure successful infections. The bacterial pathogen L. pneumophila appears to activate the major immune regulator NF-κ B in different phases of infection by mechanisms that are either independent of or dependent on its Dot/Icm transporter, which is essential for virulence 2,3 . The activation seen after the initial phase of infection is probably attributed to Dot/Icm effectors such as LegK1 and LnaB (refs 5, 6 ). Whereas activation at late phases of infection is of importance in multiple respects, including the induction of genes involved in cell survival 2 , virulenceindependent activation of NF-κ B is probably detrimental to bacterial colonization. At least two lines of evidence suggest that the function of MavC is to counteract the effects of NF-κ B activation occurring in the early phase of infection. First, this gene is highly expressed in bacteria grown to post-exponential phase ( Supplementary Fig. 2b ). Second, MavC-induced reduction of Iκ Β α in infected cells reached the lowest level within the first 30 min after bacterial uptake (Fig. 5c ).
E2 enzymes have emerged as important players in the formation of specific ubiquitin codes by directly controlling chain type synthesis, yet our understanding of their function and regulation remains limited 28, 29 . Interestingly, although the enzymes involved remain unknown, UBE2N has been reported to be ISGylated at Lys 92 , which leads to inhibition of its E2 activity 30, 31 . Similarly, UBE2T is automonoubiquitinated at Lys 91 , a modification that also inhibits its activity 32 . Other E2s such as UbcH7, have also been shown to be regulated by mechanisms such as ubiquitination, again at a lysine residue close to the active cysteine, leading to proteasome-mediated degradation 33, 34 . Our results point to the importance of Lys 92 in the activity and regulation of UBE2N, probably due to its close proximity to the catalytic Cys 87 residue. The discovery of UBE2N monoubiquitination by MavC has added another layer of complexity to the regulation of E2 activity. The nature of the potential ubiquitination of UBE2N by Ub-AA observed in our initial experiments is unclear ( Supplementary  Fig. 1) , nor is the enzyme involved in such modification. Ub-AA can be linked to UBE2N via Arg 42 , akin to that induced by members of the SidE family 11 , or by a Gln residue by enzymes similar to MavC or other as yet uncharacterized mechanisms. Because TGases are widely present in eukaryotic cells 19 , it is possible that some of these enzymes also regulate cellular signalling by catalysing ubiquitination.
Similar to established transglutaminases, MavC habours deamidase activity that attacks ubiquitin ( Supplementary Fig. 5) , an activity also reported by a recent study 35 . Several lines of evidence indicate that ubiquitination of UBE2N, rather than ubiquitin deamidation by MavC, is responsible for its inhibition of the NF-κ B pathway. First, the inhibitory effects can be suppressed by co-expressing UBE2N K92A , a mutant that cannot be modified by MavC (Fig. 6a) . Second, MavC cannot inhibit NF-κ B activation induced by TAK1/ TAB1 or IKKβ , indicating that its point of action lies upstream of these kinases, which differs from deamidases that attack ubiquitin (Fig. 6d,e ). Third, under identical reaction conditions, the transglutamination activity of MavC is much higher than the deamidation activity against ubiquitin (Fig. 4) . Finally, whereas ubiquitination of UBE2N by MavC can be readily detected in cells infected with wildtype L. pneumophila, deamidated ubiquitin was not detectable in such cells ( Fig. 1 and Supplementary Fig. 6 ). Thus, the role of ubiquitin deamidation in the function of MavC, if any, should be minor. UBE2N is the main E2 enzyme that specifies the formation of K 63 -type ubiquitin chains 15, 28, 29 , and plays an important role in the activation of NF-κ B, a process that is clearly required during L. pneumophila infection 2, 4 . Thus, the activity of MavC mandates the requirement of enzymes that function to reverse the modification on UBE2N. Such enzymes may be of host or bacterial origin, or both, and should serve to impose temporal regulation of UNE2N activity together with MavC. Alternatively, other yet unidentified E2 enzymes not attacked by MavC may be responsible for NF-κ B activation seen in infected cells after the initial phase of infection 2 . The identification of MavC as an inhibitor for NF-κ B activation reveals that L. pneumophila modulates the activity of this immune regulator by effectors with converse biological consequences, which is akin to the reversible regulation of other cellular events such as vesicle trafficking by effectors of opposite biochemical activities 11, 36 . Interestingly. the Shigella effector OspI deamidates UBE2N to interfere with its activity 26 . Differing from the effects of MavC, which inhibits almost all known signalling branches that activate NF-κ B ( Supplementary Fig. 10 ), deamidation of UBE2N at Gln 100 by OspI only blocks its function in response to PMA via the diacylglycerol (DAG)-CBM (CARD-BCL10-MALT1) axis 26 . The targeting of UBE2N by multiple pathogens highlights its importance in immunity. Further study is required to analyse the regulation of the effects imposed by MavC and the structural basis of the mechanism of inhibition by this unique ubiquitination.
Methods
Media, bacteria strains, plasmid constructions and cell lines. L. pneumophila strains used in this study were derivatives of the Philadelphia 1 strain Lp02 (ref. 37 ) and were grown and maintained on CYE (charcoal-yeast extract) plates or in N-(2-acetamido)-2-aminoethane (ACES) buffered yeast extract (AYE) broth as previously described 37 . The mavC in-frame deletion strain was constructed as described in ref. 38 . mavC and mavC C74A genes were cloned into pZL507 (ref. 39 ) for complementation. All the L. pneumophila cluster deletion strains were gifts from R. Isberg (Tufts University) 16 . E. coli strains XL1-Blue and BL21(DE3) were used for expression and purification of all the recombinant proteins used in this study. E. coli strains were grown in Luria broth (LB). Genes for protein purifications were cloned into pQE30 (QIAGEN) or pETSUMO (Invitrogen) for expression. For ectopic expression of proteins in mammalian cells, genes were inserted into the 4xFlag CMV vector 12 or the 3xHA pCDNA3.1 vector 40 . HEK293, 293T cells were cultured in Dulbecco's modified minimal Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Raw264.7 cells were cultured in Roswell Park Memorial Institute 1640 (RPMI 1640) medium supplemented with 10% FBS. All cell lines were purchased from ATCC and authenticated. All cell lines were regularly checked for potential mycoplasma contamination by the universal mycoplasma detection kit from ATCC (cat. no. 30-1012K).
Protein purification.
A series of 10 ml overnight E. coli cultures were transferred to 400 ml LB medium supplemented with 100 μ g ml −1 of ampicillin or 30 μ g ml −1 of kanamycin, and the cultures were grown to an OD 600 of ~0.5-0.7 before induction with 0.2 mM isopropyl thio-d-galactopyranoside (IPTG). Cultures were further incubated at 18 °C for ~16-18 h. Bacteria were collected by centrifugation at 4,000g for 10 min, and were lysed by sonication in 35 ml phosphate-buffered saline (PBS). Bacteria lysates were centrifuged twice at 18,000g at 4 °C for 20 min to remove insoluble fractions and unbroken cells. Supernatant containing recombinant proteins was incubated with 1 ml Ni 2+ -NTA beads (Qiagen) at 4 °C for 2 h with agitation. Ni 2+ -NTA beads with bound protein were washed with PBS buffer containing 20 mM imidazole three times with 30× the column volume each time. Proteins were eluted with PBS containing 300 mM imidazole. Proteins were dialysed in buffer containing 25 mM Tris-HCl (pH 7.5), 150 mM NaCl and 1 mM dithiothreitol (DTT) for 16-18 h.
Transfection, infection and immunoprecipitation. Lipofectamine 3000 (Thermo Fisher Scientific) was used to transfect HEK293 or HEK293T cells grown to about 70% confluence. Different plasmids were transfected into 293T cells, respectively. Transfected cells were collected and lysed with radioimmunoprecipitation assay buffer (RIPA buffer, Thermo Fisher Scientific) at 16-18 h post transfection. Cell lysates were resolved by SDS-PAGE gels and transferred to nitrocellulose membranes for immunoblotting analysis with specific antibodies. When needed, immunoprecipitation was performed with lysates of transfected cells with Flag-or HA-specific antibody-coated agarose beads (Sigma cat. nos. F1804 and A2095, respectively) at 4 °C for 4 h. Beads were washed with pre-cold RIPA buffer or respective reaction buffers three times and resolved by SDS-PAGE gels followed by immunoblotting analysis with specific antibodies or silver staining following the manufacturer's protocols (Sigma cat. no. PROTSIL1).
For all L. pneumophila infection experiments, L. pneumophila strains were grown to post-exponential phase (OD 600 = 3.2-3.8) in AYE broth. Complementation strains were induced with 0.2 mM IPTG for 4 h at 37 °C before infection. Raw264.7 cells were infected with L. pneumophila strains at an MOI of 10 for 2 h. HEK293 cells transfected to express the Fcγ II receptor were infected with opsonized L. pneumophila strains at an MOI of 10 for 2 h. L. pneumophila strains were opsonized by incubating bacteria with L. pneumophila-specific anti-sera at a dilution of 1:500. Cells were collected and lysed with 0.2% saponin on ice for 30 min. Cell lysates were resolved by SDS-PAGE and followed by immunoblotting analysis with the specific antibodies. L. pneumophila bacteria lysates were resolved by SDS-PAGE followed by immunoblotting with MavC-specific antibody to examine the expression of MavC, and isocitrate dehydrogenase (ICDH) was probed as loading control with antibodies as previously described 39 . For intracellular growth, infection was performed at an MOI of 0.05 and the total bacterial counts were determined at 24 h intervals as described in ref. 38 . For immunostaining, Raw264.7 cells were challenged by L. pneumophila at an MOI of 2 for 2 h. To detect deamidated ubiquitin in cells, HEK293 cells were transfected for 14 h and U937 cells were infected with relevant L. pneumophila strains for 2 h at an MOI of 10.
In vitro ubiquitination assays. For canonical ubiquitination dropout assays, 5 μ g His 6 − 3xHA-ubiquitin, 0.2 μ g E1, 1 μ g UBE2N, 1 μ g UBE2V2, 1 μ g MavC, 2 mM ATP and 5 mM Mg 2+ were added into a 25 μ l reaction containing 50 mM Tris-HCl (pH 7.5) and 1 mM DTT. When needed, a specific component was withdrawn from the reaction. The reactions were performed at 37 °C for 2 h.
For non-canonical MavC-mediated ubiquitination reaction, 5 μ g His 6 − 3xHAubiquitin or His 6 -ubiquitin, 0.5 μ g UBE2N, 0.05 μ g MavC and 5 mM Mn 2+ were included in a 25 μ l reaction system containing 50 mM Tris-HCl (pH 7.5) and 1 mM DTT. The reaction was allowed to proceed for 1 h at 37 °C. When needed, 50 μ g of native or boiled lysates of E. coli, yeast or 293T cells were added into the reactions. To obtain native lysates, E. coli and yeast cells were lysed by sonication, and HEK293T cells were lysed by RIPA buffer without EDTA. Boiled lysates were prepared by treating cells at 100 °C for 5 min. Concentrations of lysates were measured by the Bradford assay.
For ubiquitin derivative ubiquitination assays, 5 μ g His-tagged wild-type or ubiquitin mutants was incubated with 0.5 μ g UBE2N, 0.05 μ g MavC or MavC C74A in 25 μ l reactions, each containing 50 mM Tris-HCl (pH 7.5), 5 mM Mn 2+ and 1 mM DTT at 37 °C for 1 h. All ubiquitin derivatives were obtained from Boston Biochem.
K63 polyubiquitin chain synthesis assay. His 6 − 3xHA-ubiquitin (10 μ g) and 0.5 μ g UBE2N were pretreated with 0.05 μ g MavC or MavC C74A in a 25 μ l reaction system containing 50 mM Tris-HCl (pH 7.5) and 1 mM DTT at 37 °C for 4 h. After pretreatment, reactions were supplemented with 0.5 μ g E1, 0.5 μ g UBE2V2, 2.5 μ g TRAF6, 2 mM ATP and 5 mM Mg 2+ , and incubated at 37 °C for additional 10 min.
Antibodies and immunoblotting. Purified His 6 -MavC was used to raise rabbit specific antibodies using a standard protocol (Pocono Rabbit Farm & Laboratory). The antibodies were affinity-purified as described in ref. 38 . For immunoblotting, samples resolved by SDS-PAGE were transferred onto 0.2 μ m nitrocellulose membranes (Pall Life Sciences cat. no. 66485). Membranes were blocked with 5% non-fat milk, incubated with the appropriate primary antibodies: anti-UBE2N (Cell Signaling cat. no. 6999S, Thermo Fisher Scientific cat. no. 37-1100), 1:1,000; anti-Flag (Sigma cat. no. F1804), 1:2,000; anti-HA (Santa Cruz cat. no. sc-7392 1:1,000, Roche cat. no. 11867423001 1:5,000), anti-ICDH 39 , 1:10,000, anti-actin (Sigma cat. no. A2103), 1:5,000, anti-tubulin (DSHB, E7) 1:10,000, anti-Ub K63 (Millipore cat. no. 05-1308), 1:1,000, anti-Iκ Bα (Cell Signaling cat. no. 9242S), 1:1,000, anti-Ub (Santa Cruz cat. no. sc-8017), 1:1,000, anti-p-Iκ Bα (Cell Signaling cat. no. 9246S), 1:1,000, anti-UBE2K (Cell Signaling cat. no. 8226S), 1:1,000, anti-UBE2S (Cell Signaling cat. no. 11878S), 1:1,000, anti-UBE2E2 (Abcam cat. no. Ab177485), 1:1,000, anti-His (Sigma cat. no. H1029), 1:10,000, anti-p65 (Cell Signaling cat. no. 8242S), 1:500. Membranes were then incubated with an appropriate IRDye infrared secondary antibody and scanned using an Odyssey infrared imaging system (LiI-COR Biosciences).
LC-MS/MS analysis.
Protein bands corresponding to MavC-treated ubiquitin were excised from SDS-PAGE and digested with trypsin as described in ref. 41 . Mass spectrometry experiments were performed at the Pacific Northwest National Laboratory (PNNL). The digested peptides were analysed in a C18 reversed-phase column connected to an ultraperformance liquid chromatograph (Acquity, Waters) by separating with a gradient of acetonitrile (ACN)/0.1% formic acid (solvent B) versus 0.1% formic acid in water (solvent A): 1% B to 8% B over 5 min and 8% B to 40% B over 95 min at 300 nl min −1 . Eluting peptides were directly analysed in an Orbitrap mass spectrometer (Q-Exactive Plus, Thermo Fisher Scientific) by subjecting the top 12 most intense ions to higher-energy collisional dissociation (HCD) fragmentation with a normalized collision energy of 30.
Samples for protein identification obtained by immunoprecipitation and crosslinking products between ubiquitin and UBE2N were analysed at the Biological Mass Spectrometry of the Chemistry Department at Indiana University, Bloomington. The protein mixture was reduced and alkylated, followed by addition of trypsin at a 1:100 (wt/wt) ratio. After digestion overnight at 37 °C, the resulting peptides were desalted by Zip-tip and injected into an Easy-nLC 100 high-performance liquid chromatography system coupled to an Orbitrap Fusion Lumos mass spectrometer (Thermo Scientific). Peptide samples were loaded onto a home-made C18 trap column (75 μ m × 20 mm, 3 μ m, 100 Å) in 0.1% formic acid. The peptides were separated using an Acclaim PepMapTM RSLC C18 analytical column (75 μ m × 150 mm, 2 μ m, 100 Å) using an ACN-based gradient (solvent A: 0% ACN, 0.1% formic acid; solvent B: 80% ACN, 0.1% formic acid) at a flow rate of 300 nl min −1 . A 30 min gradient was as follows: 0-0.5 min, 2-6% B; 0.5-24 min, 6-40% B; 24-26 min, 40-100% B; 26-30 min, 100% B, followed by re-equilibration to 2% B. Electrospray ionization was carried out with a nanoESI source at 260 °C capillary temperature and 1.8 kV spray voltage. The mass spectrometer was operated in data-dependent acquisition mode with a mass range 400 to 1,600 m/z. The precursor ions were selected for MS/MS analysis in an Orbitrap with 3 s cycle time using HCD at 28% collision energy. The intensity threshold was set at 4 × 10 5 . The dynamic exclusion was set with a repeat count of 1 and exclusion duration of 30 s. The resulting data were searched in Protein Prospector (http://prospector. ucsf.edu/prospector/mshome.htm) against the 6xHis-3HA-UB-Q40E and 6xHis-UBE2N sequences. Carbamidomethylation of cysteine residues was set as a fixed modification. Protein N-terminal acetylation, oxidation of methionine, protein N-terminal methionine loss and pyroglutamine formation were set as variable modifications. A total of three variable modifications were allowed. Trypsin digestion specificity with one missed cleavage was allowed. The mass tolerance for precursor and fragment ions was set to 10 ppm for both. The crosslinked peptide search option was selected in Protein Prospector, with the crosslinking reagent designated as EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride). EDC-style crosslinking involves the formation of a zero-length isopeptide bond between an amine group and a carboxylic acid, as would be expected for ubiquitin conjugation Peptide and protein identification cutoff scores were set to 15 and 22, respectively. All putative crosslinked spectra were manually inspected. In both case, data were analysed manually by de novo sequencing or StavroX v.3.6.0.1 42 using default parameters.
To detect deamidated ubiquitin from cells, cells were lysed in 50 µ l of a buffer containing 50 mM NH 4 HCO 3 , 8 M urea and 5 mM DTT and incubated for 30 min at 37 °C. After this incubation period samples were diluted eightfold with 50 mM NH 4 HCO 3 , and CaCl 2 was added to a final concentration of 1 mM from a 1 M stock solution. The digestion was carried out overnight at 37 °C with 2 µ g of sequencinggrade trypsin (Promega). The samples were desalted using 1 ml C18 cartridges (50 mg, Stracta, Phenomenex) according to the manufacturer's recommendations. The samples were dried in a vacuum centrifuge, resuspended in water and quantified by bicinchoninic acid assay (Thermo Fisher Scientific). A total of 500 ng of digested peptides was loaded into a trap C18 column and the separation was carried out in a C18 column (70 cm × 360 µ m (OD) × 75 µ m (ID) silica tubing (Polymicro) packed with 3 µ m Jupiter C18 stationary phase, Phenomenex). Peptides were eluted at a flow rate of 300 nl min −1 with a gradient of ACN in water, both containing 0.1% formic acid: 1-8% ACN solvent in 2 min, 8-12% ACN in 18 min, 12-30% ACN in 55 min, 30-45% ACN in 22 min, 45-95% ACN in 3 min, hold for 5 min in 95% ACN and 99-1% ACN in 10 min. Eluting peptides were analysed in an Orbitrap mass spectrometer (Velos, Thermo Fisher Scientific) by targeting specific peptides to fragmentation (PRM, parallel-reaction monitoring). The normalized collision energy was set to 30 in the HCD cell and spectra were collected with an m/z range of 50-2,000 and resolution of 15,000 at 400 m/z. Collected spectra were analysed using Xcalibur v2.2 (Thermo Fisher Scientific). Extracted-ion chromatograms were plotted using a tolerance of ± 10 mDa and smoothed with 11 points using the Gaussian function. Quantification was carried out by comparing peak areas, and significant differences in ubiquitin deamidation profiles were determined by t-test assuming two tails and equal variance between samples.
In vitro deamidation of ubiquitin and Nedd8, and native PAGE. Ten μ g ubiquitin or Nedd8 was incubated with 1 μ g MavC or MavC C74A in a 50 μ l reaction in a buffer containing 50 mM Tris-HCl (pH 8.8) at 37 °C for 2 h. Reaction mixtures (20 μ l) were mixed with 5 μ l 5x native gel loading buffer (pH 8.8) and loaded onto 10% native gels, and gels were run in a Tris-glycine buffer (pH 8.8). Protein bands were visualized by Coomassie brilliant blue staining.
NF-κB luciferase reporter assay. HEK293T were grown to 70% confluence in 24-well plates, and transfected with 75 ng NF-κ B reporter plasmids 43 and 150 ng 4xFlag CMV empty vector, 4xFlag-MavC or 4xFlag-MavC C74A vectors. For NF-κ B epistasis analysis, 150 ng of corresponding plasmids was used, while 75 ng of plasmid that directs the expression of Renilla luciferase in pRL-SV40 (Promega) was co-transfected as internal control. At 16-18 h post transfection, cells with treated with 20 ng ml −1 TNF-α or 50 nM PMA for 4 h. The cells were then collected and lysed for NF-κ B luciferase reporter assay following the manufacturer's protocols (Promega cat. no. E1910).
Immunostaining. HEK293 cells or Raw264.7 cells were seeded at 2 × 10 5 per well. HEK293 cells were transfected with corresponding plasmids and Raw264.7 cells were infected with corresponding strains at an MOI of 2. At 16-18 h post HEK293 cells transfection and 2 h post Raw264.7 cells infection, cells were washed with PBS and fixed by 4% formaldehyde solution for 15 min at room temperature, permeabilized by 0.2% Triton solution for 5 min at room temperature, and blocked with 4% goat serum for 30 min at 37 °C. Bacteria were stained with anti-rat L. pneumophila serum at a dilution of 1:10,000 for 1 h, p65 was stained with the p65 specific antibody (Cell Signaling cat. no. 8242S) at a dilution of 1:500, Flag peptide was stained with the Flag peptide specific antibody(Sigma cat. no. F1804) at a dilution of 1:400 for 4 h, and nucleus was stained with DAPI, then stained with Alexa Fluor 594 or Alexa Fluor 488 correspondingly (Thermo Fisher Scientific). At least 300 cells were scored. 
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Antibodies
Antibodies used Purified His6-MavC was used to raise rabbit specific antibodies using a standard protocol (Pocono Rabbit Farm & Laboratory). The antibodies were affinity purified as describe38. For immunoblotting, samples resolved by SDS-PAGE were transferred onto 0.2 μm nitrocellulose membranes (Pall Life Sciences cat# 66485). Membranes were blocked with 5% non-fat milk, incubated with the appropriate primary antibodies: anti-UBE2N (Cell signaling, cat# 6999S, Thermo Fisher Scientific, cat# 37-1100), 1:1,000; anti-Flag (Sigma, Cat# F1804), 1: 2000; anti-HA (Santa Cruz, cat# sc-7392 1:1,000, Roche, cat# 11867423001 1:5,000), anti-ICDH39, 1:10,000, anti-actin (Sigma, cat# A2103), 1:5,000, anti-tubulin (DSHB, E7) 1:10,000, anti-Ub K63 (Millipore, cat# 05-1308), 1:1,000, anti-IkBα (Cell signaling, cat# 9242S), 1:1,000, anti-Ub (Santa Cruz cat#sc-8017), 1:1,000, anti-p-I?Bα (Cell Signaling, cat# 9246S), 1:1000, anti-UBE2K (Cell Signaling, cat# 8226S), 1:1000, anti-UBE2S (Cell Signaling, cat# 11878S), 1:1000, anti-UBE2E2 (Abcam, cat# Ab177485), 1:1000, anti-His (Sigma, cat# H1029), 1:10,000, anti-p65 (Cell signaling, cat# 8242S), 1:500. Membranes were then incubated with an appropriate IRDye infrared secondary antibody and scanned using an Odyssey infrared imaging system (Li-Cor's Biosciences). 
Validation
Mycoplasma contamination
Contamination tested by using the universal mycoplasma detection kit from ATCC (cat# 30-1012K).
